Tested variables | Treated patients (n=25) | Untreated patients (n=26) | P-value | OR [95% CI] | |
---|---|---|---|---|---|
Clinical criteria | |||||
BMI < 18 (kg/m2) | 13/24 (54.2) | 5/23 (21.7) | 0.026 | 4.25 [1.18-15.2] | |
Weight loss > 5% | 17 (68) | 10 (38.5) | 0.05 | 3.4 [1.07-10.77] | |
fatigue | 13 (52) | 7 (27) | 0.071 | 2.94 [0.9-9.46] | |
chronic cough | 16 (64) | 14 (54) | 0.572 | 1.52 [0.49-4.69] | |
night sweats | 5 (20) | 3 (11.5) | 0.465 | 1.92 [0.41-9.05] | |
hemoptysis | 8 (32) | 1 (3.8) | 0.026 | 11.8 [1.3-102.8] | |
Microbiological criteria | |||||
AFB-positive sputum sample on direct examination | 13 (52) | 8 (30.8) | 0.160 | 2.44 [0.77-7.65] | |
NTM-positive culture NTM on lower respiratory tract sample | 2 (1-2.3) | 1 (1-1.8) | 0.044 | 1.79 [1-3.2] | |
Functional criteria | |||||
FEV1 (L) | 1.6 (1.2-2.2) | 1.9 (1.2-2.5) | 0.554 | 0.72 [0.34-1.51] | |
Immunological and nutritional status | |||||
total lymphocyte count (G/L) | 1.3 (1.2-1.7) | 1.4 (1.1-2.1) | 0.388 | 0.95 [0.86-1.04] | |
CD4+ lymphocyte count (%) | 54 (4.5-61.5) | 40 (37.8-44.3) | 0.031 | 1.07 [0.95-1.21] | |
serum albumin (mg/L) | 39.5 (36-43) | 39 (33-42.5) | 0.481 | 1.05 [0.97-1.14] | |
serum pre-albumin (mg/L) | 0.21 (0.15-0.24) | 0.22 (0.15-0.25) | 0.974 | 1.25 [0-1.48] | |
vitamin D deficiency | 6/10 (60) | 6/7 (86) | 0.338 | 0.25 [0.02-2.95] | |
Co-infection(s) | |||||
Mycobacterium tuberculosis | 1 (4) | 1 (4) | 0.35 | 1.04 [0.06-17.6] | |
Pseudomonas spp. | 2 (8) | 3 (11.5) | 1 | 0.68 [0.1-4.4] | |
Aspergillus spp. | 15 (60) | 5 (19.2) | 0.004 | 6.3 [1.8-22.2] | |
Radiologic features at diagnosis | |||||
nodule(s) (≥ 10mm) | 12 (48) | 7/23 (30) | 0.25 | 2.11 [0.65-6.9] | |
cluster(s) of micronodules (< 5mm) | 16 (64) | 10/23 (44) | 0.246 | 2.31 [0.72-7.4] | |
cavitation(s) | 18 (72) | 8/23 (35) | 0.019 | 4.82 [1.42-16.4] | |
bronchiectasis | 14 (56) | 11/23 (48) | 0.773 | 1.39 [0.45-4.3] | |
emphysema | 9 (36) | 11/23 (48) | 0.559 | 0.61 [0.19-1.95] | |
Radiologic review | |||||
regression | 8/23 (35) | 4/13 (31) | 1 | 1.2 [0.28-5.15] | |
stabilization | 9/23 (39) | 6/13 (46) | 0.736 | 0.75 [0.19-2.97] | |
worsening | 6/23 (26) | 3/13 (23) | 1 | 1.18 [0.24-5.8] |